Abstracts tagged "ANCA"

Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Linda Vergel Orduz¹, Alejandro Brigante ², Diego Marino ³, Natalia Perrotta ³, Romina Hassan ⁴, Gisele Verna ⁵, Adriana Hamaui ⁶, Eduardo Kerzberg ⁷ and Diana Dubinsky ⁶, ¹Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Sanatorio Güemes, Buenos Aires, Argentina, ⁷Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
Abstract Number: 906 • 2018 ACR/ARHP Annual Meeting
Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵ and Peter A. Merkel^4,6, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:Although a link between gut microbiome and autoimmune diseases has been suggested, there is a gap in the understanding of the gut microbiome in ANCA-associated…
Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
Abstract Number: 2734 • 2018 ACR/ARHP Annual Meeting
The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides
Mete Kara¹, Mehmet Nedim Taş¹, Raika Durusoy², Sertaç Ketenci¹, Mete Pekdiker³, Hande Ece Öz⁴, Gülay Aşçı⁵, Gokhan Keser⁶ and Kenan Aksu⁴, ¹Rheumatology, Ege University Medical Faculty, izmir, Turkey, ²Public Health, Ege University Medical Faculty, izmir, Turkey, ³Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, ⁴Rheumatology, Ege University Medical Faculty, İzmir, Turkey, ⁵Nephrology, Ege University Medical Faculty, İzmir, Turkey, ⁶Rheumatology, Ege University Medical Faculty, Izmir, Turkey
Background/Purpose: Elderly patients with ANCA associated vasculitides (AAV) seem to have clinical differences compared to younger patients. The aim of this study is to compare…
Abstract Number: 907 • 2018 ACR/ARHP Annual Meeting
Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Gwen Thompson¹, Marta Casal Moura², Darlene Nelson¹, Amber Hummel¹, Dieter E. Jenne³, Fernando Fervenza⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol Langford⁷, Joseph W. McCune⁸, Peter A. Merkel⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Robert F. Spiera¹², Eugene William St. Clair¹³, Steven R. Ytterberg¹⁴, John H. Stone¹⁵, William H. Robinson¹⁶, Yuan-Ping Pang¹ and Ulrich Specks¹⁷, ¹Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, ³Helmholtz Zentrum München, Munich, Germany, ⁴Nephrology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶University of Gronigen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Hospital for Special Surgery, New York, NY, ¹³Medicine, Duke University Medical Center, Durham, NC, ¹⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁶Stanford, Stanford, CA, ¹⁷Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Human-murine chimeric variants have been used to study specific epitope recognition by anti-neutrophil cytoplasmic antibodies (ANCAs) targeting proteinase 3 (PR3) in patients with ANCA-associated…
Abstract Number: 1958 • 2018 ACR/ARHP Annual Meeting
Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology
Marcia Friedman¹, Donseok Choi^1,2,3,4, Steven Planck^1,4, James T. Rosenbaum⁵ and Cailin Sibley¹, ¹Oregon Health & Science University, Portland, OR, ²OHSU-PSU School of Public Health, Portland, OR, ³Graduate School of Dentistry, Kyung Hee Universtiy, Seoul, Korea, Republic of (South), ⁴Casey Eye Institute, Portland, OR, ⁵Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: In recent years, several studies have characterized the gene expression signatures of different tissues affected by ANCA-associated vasculitis (AAV). The purpose of this study…
Abstract Number: 2735 • 2018 ACR/ARHP Annual Meeting
Identifying ANCA-Associated Vasculitis Cases in Electronic Health Records Using Natural Language Processing
Zachary Wallace¹, John H. Stone² and Hyon K. Choi³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Epidemiologic studies of ANCA-associated vasculitis (AAV) using large data sets are often limited by the lack of validated definitions of AAV cases that can…
Abstract Number: 1746 • 2018 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Hiromi Matsushita¹, Yoshioki Yamasaki², Yukiko Takakuwa³, Hidehiro Yamada⁴ and Kimito Kawahata³, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan
Background/Purpose: ANCA-associated vasculitis including microscopic polyangiitis (MPA) involves multiple organs including lungs. Clinical characteristics and impact on long-term survival in MPA patients with interstitial lung disease (ILD) have not…
Abstract Number: 1965 • 2018 ACR/ARHP Annual Meeting
Association of HLA Class II Alleles with Relapse and Interstitial Lung Disease in Myeloperoxidsae (MPO) -ANCA Positive Vasculitis in a Japanese Population
Aya Kawasaki¹, Ken-ei Sada², Fumio Hirano^3,4, Shigeto Kobayashi⁵, Hidehiro Yamada⁶, Hiroshi Furukawa^1,7, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida¹¹, Shigeto Tohma^12,13, Shoichi Ozaki⁶, Hiroshi Hashimoto¹⁴, Hirofumi Makino¹⁵, Yoshihiro Arimura¹⁶, Masayoshi Harigai¹⁷ and Naoyuki Tsuchiya¹, ¹University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁴Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁵Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁶St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ⁷National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹²National Hospital Organization Tokyo Hospital, Sagamihara, Japan, ¹³National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁴Juntendo University School of Medicine, Tokyo, Japan, ¹⁵Okayama University Hospital, Okayama, Japan, ¹⁶Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁷Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: The high prevalence of microscopic polyangiitis (MPA) and myeloperoxidase (MPO)-ANCA positive patients as well as frequent occurrence of interstitial lung disease (ILD) constitute unique…
Abstract Number: 2737 • 2018 ACR/ARHP Annual Meeting
Opportunistic Infections in Medium and Small-Sized Vessel Vasculitis: Based on a Retrospectivestudy on 108 Patients
Raphaele Mestiri¹, Lafarge Antoine², Jean-Jacques Tudesq³, Marc Pineton de Chambrun⁴, Melanie Roriz⁵, Stéphane Bally⁶, Laurent Alric⁷, Damien Sène⁸, Thomas Quémeneur⁹, Cécile-Audrey Durel¹⁰, Brigitte Gilson¹¹, Alice Berezne¹², Anne-Marie Ruppert¹³, Raphaele Seror¹⁴, Philippe Guilpain¹⁵, Xavier Puéchal¹⁶, Luc Mouthon¹⁷, Loïc Guillevin¹⁶ and Benjamin Terrier¹⁸, ¹Internal Medicine, Cochin hospital, Paris, France, ²Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ³Internal Medicine, CHU Montpellier, Montpellier, France, ⁴Université Pierre et Marie Curie, Paris, France, ⁵Université Paris-Diderot, Paris, France, ⁶Nephrology, CH Chambery, Chambery, France, ⁷Internal Medicine, CHU Toulouse, Toulouse, France, ⁸Lariboisière Hospital, Paris Diderot University, Paris, France, ⁹Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ¹⁰Internal Medicine, Hôpital Edouard Herriot, lyon, France, ¹¹Internal Medicine, CH Verdun, Verdun, France, ¹²Internal Medicine, CH Annecy, Annecy, France, ¹³Pulmonology, Tenon hospital, Paris, France, ¹⁴Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ¹⁵Montpellier, Montpellier, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ¹⁸Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France
Background/Purpose: Overall survival has been markedly improved during the last decades in systemic vasculitis. In contrast, the use of immunosuppressive agents led to an increased…
Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 1967 • 2018 ACR/ARHP Annual Meeting
Detection of Association of Long Noncoding RNA ATP6V0E2-AS1 Single Nucleotide Polymorphism with Susceptibility to Myeloperoxidase-ANCA Associated Vasculitis Based on Transcriptome Analysis
Yuka Iwahashi^1,2, Aya Kawasaki^1,2, Takayo Tsuchiura³, Ken-ei Sada⁴, Fumio Hirano^5,6, Daisuke Tsukui⁷, Shigeto Kobayashi⁸, Hidehiro Yamada⁹, Hiroshi Furukawa^1,2,10, Kenji Nagasaka¹¹, Takahiko Sugihara¹², Nao Nishida³, Kunihiro Yamagata¹³, Takayuki Sumida¹⁴, Shigeto Tohma^10,15, Shoichi Ozaki⁹, Hiroshi Hashimoto¹⁶, Hirofumi Makino¹⁷, Yoshihiro Arimura¹⁸, Hajime Kono¹⁹, Masayoshi Harigai²⁰ and Naoyuki Tsuchiya^1,2, ¹University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ²University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ³Genome Medical Science Project, National Center for Global Health and Medicine, Research Center for Hepatitis and Immunology, Ichikawa, Japan, ⁴Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁵Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁶Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁷Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁸Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁹St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ¹⁰National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ¹¹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹³University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁵National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁶Juntendo University School of Medicine, Tokyo, Japan, ¹⁷Okayama University Hospital, Okayama, Japan, ¹⁸Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁹Teikyo University School of Medicine, Department of Internal Medicine, Tokyo, Japan, ²⁰Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: Because of the low prevalence, only three genome-wide association studies, all from the Caucasian populations, have been reported on ANCA-associated vasculitis (AAV) thus far;…
Abstract Number: 2738 • 2018 ACR/ARHP Annual Meeting
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Peter A. Merkel¹, David Jayne², Thomas J. Schall³, Pirow Bekker³ and Jan Hillson³, ¹Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³ChemoCentryx, Mountain View, CA
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPeter A. Merkel1, David…
Abstract Number: 1748 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA-Positive Vasculitis Patients
Andy Abril¹, Minkyung Kwon,², Isabel Mira-Avendano³, Carlos Rojas⁴ and Andras Khoor⁵, ¹Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL, ³Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL, ⁴Radiology, Mayo Clinic, Jacksonville, FL, ⁵Pathology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Rarely, ANCA-positive vasculitis patients are found to have interstitial lung disease (ILD). Clinical characteristics and prognosis are not well known in these patients. The…

« Previous Page
1
…
7
8
9
10
11
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].